New anti-emetic treatments

Annals of Oncology

Volumn 18, Issue SUPPL. 9, 2007, Pages

  Roila, F ^a   Garassino, M ^b   Fatigoni, S ^a  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; CASOPITANT; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; DOXORUBICIN; GABAPENTIN; GHRELIN; GRANISETRON; INDOMETACIN; LORAZEPAM; MELOXICAM; METOCLOPRAMIDE; MIDAZOLAM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OLANZAPINE; ONDANSETRON; PALONOSETRON; PROSTAGLANDIN SYNTHASE INHIBITOR; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN 4 ANTAGONIST; TROPISETRON;

ANOREXIA; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DROWSINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; TREATMENT DURATION; XEROSTOMIA; CHEMICALLY INDUCED DISORDER; NAUSEA; NEOPLASM; REVIEW; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; NAUSEA; NEOPLASMS; VOMITING;

EID: 36049025554     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm293     Document Type: Conference Paper

References (24)

1. Roila F, Fatigoni S, Ciccarese G. Daily challenges in oncology practice. What do we need to know about antiemetics? Ann Oncol 2006; 17 (Suppl. 10): 90-94.
2. The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia International Consensus Conference. Ann Oncol 2006; 17: 20-28.
3. Kris MG, Hesketh PJ, Somerfield MR et al. American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 2006; 24: 2932-2947.
4. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97: 3090-3098.
5. Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112-4119.
6. Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patents with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005; 23: 2822-2830.
7. Eisenberg P, MacKintosh FR, Ritch P et al. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: A dose-ranging clinical study. Ann Oncol 2004; 15: 330-337.
8. Aapro MS, Grunberg SM, Manikhas GM et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17: 1441-1449.
9. Gralla R, Lichinitser M, Van der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron, Ann Oncol 2003; 14: 1570-1577.
10. Eisenberg P, Figueroa-Vadillo J, Zamora R et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3-receptor receptor antagonist. Cancer 2003; 98: 2473-2482.
11. Grote T, Hajdenberg J, Cartmell A et al. Combination therapy for chemotherapy-induced nausea and vomiting in patents receiving moderately emetogenic chemotherapy: Palonosetron, dexamethasone, and aprepitant. J Support Oncol 2006; 4: 403-408.
12. Grunberg S, Dugan M, Chassereau L et al. Prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with a 1-day 3-drug antiemetic regimen - Preliminary report. Support Care Cancer 2006; 14: 596-597.
13. Arpornwirat W, Albert I, Hansen VL et al. Multicenter, randomized, double-blind, ondansetron-controlled, dose-ranging, parallel group trial of the neurokinin-1 receptor antagonist casopitant mesylate for chemotherapy-induced nausea/vomiting in patients receiving moderately emetegenic chemotherapy. Proc. ASCO 2006; 24: 471s (abstr. 8512).
14. Rolsky J, Ramlau R, Dediu M et al. Randomized phase II trial of the neurokinin-1 receptor antagonist casopitant mesylate with ondansetron/ dexamethasone for chemotherapy-induced nausea/vomiting in patients receiving highly emetogenic chemotherapy. Proc. ASCO 2006; 24: 471s (abtr. 8513).
15. Srivastava M, Brito-Dellan N, Davis MP et al. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer, J Pain Symptom Manage 2003; 25: 578-582.
16. Passik SD, Lundberg J, Kirsh K et al. A pilot exploration of the antiemetic activity of olanzapine (Zyprexa) for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage 2002; 23: 526-532.
17. Passik SD, Kirsh KL, Theobald DE et al. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage 2003; 25: 485-488.
18. Passik SD, Navari RMI, Jung SH et al. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: A Hoosier Oncology Group study. Cancer Invest 2004; 22: 383-388.
19. Navari RM, Einhorn LH, Passik SD et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group study. Support Care Cancer 2005; 13: 529-534.
20. Potanovich LM, Pisters KM, Kris MG et al. Midazolam in patients receiving anticancer chemotherapy and antiemetics. J Pain Symptom Manage 1991; 8: 519-524.
21. Mandalà M, Cremonesi M, Rocca A et al. Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: A phase II study. Support Care Cancer 2005; 13: 375-380.
22. Guttuso T, Roscoe J, Griggs J. Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet 2003; 361: 1703-1705.
23. Rudd JA, Ngan MP, Wai MK et al. Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin, Neurosci Lett 2006; 392: 79-83.
24. Rubenstein EB, Slusher BS, Rojas C et al. New approaches to chemotherapy-induced nausea and vomiting: From neuropharmacology to clinical investigations. Cancer J 2006; 12: 341-347.